H.C. Wainwright analyst Edward White reiterated a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $4.00. The company’s shares closed yesterday at $0.91.
According to TipRanks, White is an analyst with an average return of -10.6% and a 30.88% success rate. White covers the Healthcare sector, focusing on stocks such as SAB Biotherapeutics, TG Therapeutics, and InflaRx.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAB Biotherapeutics with a $3.50 average price target, which is a 286.74% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $3.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on SAB Biotherapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $581.1 thousand and a GAAP net loss of $7.35 million. In comparison, last year the company earned a revenue of $11.8 million and had a net profit of $985.86 thousand
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
Read More on SABS:
- SAB Biotherapeutics to host rvirtual research and development day
- SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention
- SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations
- SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
- SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
